EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation

Antonella Bruzzese, Enrica Antonia Martino iD, Santino Caserta iD, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino iD, Fortunato Morabito iD, Ernesto Vigna, Massimo Gentile iD

Antibodies · 04.08.2026 · 15 (4) · 69

DOI: 10.3390/antib15040069 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 04.08.2026. Verfasst von Antonella Bruzzese und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale della Repubblica snc, 87100 Cosenza, Italy. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts and the persistence of leukemic stem cells (LSCs) within a profoundly remodeled bone marrow (BM) microenvironment. Despite advances in molecular stratification and the introduction of targeted agents, long-term outcomes remain unsatisfactory, particularly in older and high-risk patients. Increasing evidence indicates that leukemogenesis and treatment resistance are critically sustained by a permissive immune milieu, in which LSCs, myeloid-derived suppressor cells, leukemia-associated macrophages, and dysfunctional T and NK cells shape an immunosuppressive “leukemic niche.” This evolving understanding has renewed interest in immune-based strategies capable of restoring effective antitumor immunity. Bispecific antibodies (bsAbs) are engineered molecules designed to engage AML-associated antigens while simultaneously recruiting and activating immune effector cells, most commonly T cells or NK cells. By promoting immune synapse formation independently of major histocompatibility complex expression and conventional co-stimulatory pathways, bsAbs can overcome several mechanisms of immune escape. In this review, we summarize the biological rationale for immunotherapy in AML, with a focus on the role of the BM microenvironment and immune dysregulation. We then discuss the structural and functional properties of IgG-like and non-IgG-like bsAbs, key antigenic targets such as CD33, CD123, CD70 and others, and the main T-cell- and NK-cell-engaging platforms under clinical investigation. Finally, we highlight emerging clinical data, principal toxicities, and the challenges of integrating bsAbs into existing treatment algorithms, including combinations with hypomethylating agents, BCL-2 inhibitors, and allogeneic stem cell transplantation. A deeper understanding of AML immune biology and antigen expression patterns will be essential to optimize bsAb design, maximize therapeutic benefit, and minimize on-target off-tumor toxicity.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiabispecific antibodiesbone marrow microenvironmentimmunotherapyleukemic stem cells

Autor:innen und Institutionen

  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Viale della Repubblica snc, 87100 Cosenza, Italy.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, 88100 Catanzaro, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.
  • AIL Sezione di Cosenza, 87100 Cosenza, Italy.

ORCID-Profile: Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile

Zitieren

APA

Bruzzese, A., Martino, E. A., Caserta, S., Alvaro, M. E., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Morabito, F., Vigna, E., & Gentile, M. (2026). Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation. Antibodies, 15(4), 69. https://doi.org/10.3390/antib15040069

Vancouver

Bruzzese A, Martino EA, Caserta S, Alvaro ME, Amodio N, Lucia E, et al. Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation. Antibodies. 2026;15(4):69. doi:10.3390/antib15040069

BibTeX
@article{Bruzzese2026,
  author = {Bruzzese, Antonella and Martino, Enrica Antonia and Caserta, Santino and Alvaro, Maria Eugenia and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Morabito, Fortunato and Vigna, Ernesto and Gentile, Massimo},
  title = {Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {69},
  doi = {10.3390/antib15040069}
}
Kostenlos starten →